{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:16:01Z","timestamp":1790050561062,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Mohs micrographic surgery (MMS) is a low-risk penile cancer management option. However, contemporary patients\u2019 short-term oncologic control and preoperative characteristics predicting reconstruction needs are undefined. This study assesses MMS\u2019s oncologic efficacy for low-risk penile cancer and identifies baseline predictors of post-resection reconstruction referral.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed 73 adult males with 78 penile cutaneous malignancies treated with MMS from 2005 to 2019. Patients underwent MMS with or without surgical reconstruction. Demographic information, MMS operative details, lesion pathology, and short-term outcomes were recorded. Descriptive statistics for all variables were calculated, and logistic regression identified predictive factors for urologic referral for complex reconstruction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-three men with 78 lesions, all staged\u2009\u2264\u2009cT1a prior to MMS, were identified. Twenty-one men were found to have invasive SCC. Median follow-up was 2.0\u00a0years (IQR 0.8\u20135.2\u00a0years). MMS was able to clear the disease in 90.4% of cases. One patient had disease related death following progression. Dermatology closed primarily in 68% of patients. Twenty percent of patients had a complication, most commonly poor wound healing. On univariate and multivariate linear regression analysis, lesion size\u2009&gt;\u20093\u00a0cm and involvement of the glans independently predicted the need for referral to a reconstructive surgeon.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MMS for penile cancer appears to provide sound oncologic control in the properly selected patient. Involvement of a reconstructive surgeon may be needed for glandular and large lesions, necessitating early referral to a comprehensive multidisciplinary care team.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-024-04121-6","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:06:56Z","timestamp":1719396416000},"page":"3727-3732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncologic control and predictors of urologic reconstruction after Mohs micrographic surgery for low-risk penile malignancy"],"prefix":"10.1007","volume":"56","author":[{"given":"Brian D.","family":"Cortese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Chelluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Skokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess M.","family":"Lukowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Bruce","family":"Malkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Caleb","family":"Kovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"4121_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590. (Epub 2020 Jan 8. PMID: 31912902)","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4121_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/UA.UA_93_17","volume":"10","author":"P Babbar","year":"2018","unstructured":"Babbar P, Yerram N, Crane A et al (2018) Penile-sparing modalities in the management of low-stage penile cancer. Urol Ann 10(1):1\u20136. https:\/\/doi.org\/10.4103\/UA.UA_93_17. (PMID: 29416267; PMCID: PMC5791443)","journal-title":"Urol Ann"},{"key":"4121_CR3","unstructured":": National Comprehensive Cancer Network.\u00a0Penile Cancer (Version 2.2020).\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf. Accessed Sep 2020"},{"issue":"5","key":"4121_CR4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.juro.2007.07.039","volume":"178","author":"AW Shindel","year":"2007","unstructured":"Shindel AW, Mann MW, Lev RY et al (2007) Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol 178(5):1980\u20131985. https:\/\/doi.org\/10.1016\/j.juro.2007.07.039. (Epub 2007 Sep 17. PMID: 17869306)","journal-title":"J Urol"},{"issue":"9","key":"4121_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archderm.119.9.761","volume":"119","author":"NA Swanson","year":"1983","unstructured":"Swanson NA (1983) Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 119(9):761\u2013773. https:\/\/doi.org\/10.1001\/archderm.119.9.761. (PMID: 6351758)","journal-title":"Arch Dermatol"},{"issue":"5","key":"4121_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jaad.2015.01.007","volume":"72","author":"JR Etzkorn","year":"2015","unstructured":"Etzkorn JR, Sobanko JF, Elenitsas R et al (2015) Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol 72(5):840\u2013850. https:\/\/doi.org\/10.1016\/j.jaad.2015.01.007. (Epub 2015 Mar 13. Erratum in: J Am Acad Dermatol. 2017 Nov 17;: PMID: 25774012)","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4121_CR7","first-page":"518","volume":"111","author":"PA Clavien","year":"1992","unstructured":"Clavien PA, Sanabria JR, Strasberg SM (1992) Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 111(5):518\u2013526 (PMID: 1598671)","journal-title":"Surgery"},{"issue":"2","key":"4121_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae. (PMID: 15273542; PMCID: PMC1360123)","journal-title":"Ann Surg"},{"key":"4121_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bjmsu.2011.05.001","volume":"5","author":"A Myatt","year":"2012","unstructured":"Myatt A, Palit V, Burgess N et al (2012) The Uro-Clavien-Dindo system \u2013 Will the limitations of the Clavien-Dindo system for grading complications of urological surgery allow modification of the classification to encourage national adoption within the UK. Br J Med Surg Urol 5:54\u201360","journal-title":"Br J Med Surg Urol"},{"issue":"3","key":"4121_CR10","first-page":"1","volume":"20","author":"D Hossain","year":"2016","unstructured":"Hossain D, Madaan S (2016) Use of Clavien-Dindo classification in urology part 1 \u2013 pelvic surgery. Urol News 20(3):1\u20133","journal-title":"Urol News"},{"issue":"4","key":"4121_CR11","first-page":"1","volume":"20","author":"S Madaan","year":"2016","unstructured":"Madaan S, Hossain D (2016) Use of Clavien-Dindo classification in urology part 2 \u2013 upper tract. Urol News 20(4):1\u20133","journal-title":"Urol News"},{"issue":"6","key":"4121_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s0022-5347(17)49334-7","volume":"133","author":"FE Mohs","year":"1985","unstructured":"Mohs FE, Snow SN, Messing EM et al (1985) Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 133(6):961\u2013966. https:\/\/doi.org\/10.1016\/s0022-5347(17)49334-7. (PMID: 3999220)","journal-title":"J Urol"},{"issue":"11","key":"4121_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1524-4725.1987.tb02427.x","volume":"13","author":"MD Brown","year":"1987","unstructured":"Brown MD, Zachary CB, Grekin RC et al (1987) Penile tumors: their management by Mohs micrographic surgery. J Dermatol Surg Oncol 13(11):1163\u20131167. https:\/\/doi.org\/10.1111\/j.1524-4725.1987.tb02427.x. (PMID: 3668059)","journal-title":"J Dermatol Surg Oncol"},{"issue":"8","key":"4121_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/DSS.0000000000000795","volume":"42","author":"M Machan","year":"2016","unstructured":"Machan M, Brodland D, Zitelli J (2016) Penile squamous cell carcinoma: penis-preserving treatment with mohs micrographic surgery. Dermatol Surg 42(8):936\u2013944. https:\/\/doi.org\/10.1097\/DSS.0000000000000795. (PMID: 27467227)","journal-title":"Dermatol Surg"},{"issue":"2 suppl 1","key":"4121_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.urology.2010.03.003","volume":"76","author":"MR Pow-Sang","year":"2010","unstructured":"Pow-Sang MR et al (2010) Epidemiology and natural history of penile cancer. Urology 76(2 suppl 1):2\u20136","journal-title":"Urology"},{"key":"4121_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eururo.2012.02.052","volume":"62","author":"HM Alnajjar","year":"2012","unstructured":"Alnajjar HM, Lam W, Bolgeri M et al (2012) Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 62:923\u2013928","journal-title":"Eur Urol"},{"issue":"4","key":"4121_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bju.14222","volume":"122","author":"D Sri","year":"2018","unstructured":"Sri D, Sujenthiran A, Lam W et al (2018) A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int 122(4):576\u2013582","journal-title":"BJU Int"},{"key":"4121_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2017.01.024","volume":"72","author":"A Leone","year":"2017","unstructured":"Leone A, Inman B, Spiess PE (2017) Need for evidence and consensus on laser treatment for management of select primary penile tumors. Eur Urol 72:4\u20136","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04121-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:07:27Z","timestamp":1730776047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04121-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04121-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brian D. Cortese: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Raju Chelluri: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. David A. Ostrowski: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Alexander J. Skokan: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Leilei Xia: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Daniel S. Roberson: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Lauren Schwartz: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Daniel J. Lee: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Tess Lukowiak: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Thomas J. Guzzo: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. S. Bruce Malkowicz: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. Christopher Miller: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests. R. Caleb Kovell: no disclosures or conflicts of interest regarding support for the present manuscript, grants\/contacts, royalties or licenses, consulting fees, payments\/honoraria, expert testimony, support for meetings or travel, patents, participation in DSMB\/advisory board, leadership\/fiduciary relationship, stock\/options, receipt of gifts, or other interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and given the de-identified, retrospective nature of the study, it was deemed to be exempt from review by the University of Pennsylvania Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}